Literature DB >> 24101051

Preservation of cognitive function in primary CNS lymphoma survivors a median of 12 years after enhanced chemotherapy delivery.

Nancy D Doolittle1, Edit Dósa, Rongwei Fu, Leslie L Muldoon, Leeza M Maron, Meredith A Lubow, Rose Marie Tyson, Cynthia A Lacy, Dale F Kraemer, Robert W Butler, Edward A Neuwelt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24101051      PMCID： PMC3805933          DOI： 10.1200/JCO.2013.52.7747

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  8 in total

1.  Flying solo: chemotherapy without radiation for primary CNS lymphoma.

Authors:  Tracy T Batchelor
Journal:  J Clin Oncol       Date:  2013-05-28       Impact factor: 44.544

2.  Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma.

Authors:  Nancy D Doolittle; Agnieszka Korfel; Meredith A Lubow; Elisabeth Schorb; Uwe Schlegel; Sabine Rogowski; Rongwei Fu; Edit Dósa; Gerald Illerhaus; Dale F Kraemer; Leslie L Muldoon; Pasquale Calabrese; Nancy Hedrick; Rose Marie Tyson; Kristoph Jahnke; Leeza M Maron; Robert W Butler; Edward A Neuwelt
Journal:  Neurology       Date:  2013-05-17       Impact factor: 9.910

Review 3.  The impact of chemotherapy on cognitive outcomes in adults with primary brain tumors.

Authors:  Lauren E Abrey
Journal:  J Neurooncol       Date:  2012-02-17       Impact factor: 4.130

Review 4.  Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines.

Authors:  D D Correa; L Maron; H Harder; M Klein; C L Armstrong; P Calabrese; J E C Bromberg; L E Abrey; T T Batchelor; D Schiff
Journal:  Ann Oncol       Date:  2007-02-06       Impact factor: 32.976

Review 5.  Evaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future research.

Authors:  Janette Vardy; Sean Rourke; Ian F Tannock
Journal:  J Clin Oncol       Date:  2007-05-07       Impact factor: 44.544

6.  Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience.

Authors:  Lilyana Angelov; Nancy D Doolittle; Dale F Kraemer; Tali Siegal; Gene H Barnett; David M Peereboom; Glen Stevens; John McGregor; Kristoph Jahnke; Cynthia A Lacy; Nancy A Hedrick; Edna Shalom; Sandra Ference; Susan Bell; Lisa Sorenson; Rose Marie Tyson; Marianne Haluska; Edward A Neuwelt
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

7.  Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function.

Authors:  E A Neuwelt; D L Goldman; S A Dahlborg; J Crossen; F Ramsey; S Roman-Goldstein; R Braziel; B Dana
Journal:  J Clin Oncol       Date:  1991-09       Impact factor: 44.544

Review 8.  Role and relevance of neurocognitive assessment in clinical trials of patients with CNS tumors.

Authors:  Christina A Meyers; Paul D Brown
Journal:  J Clin Oncol       Date:  2006-03-10       Impact factor: 44.544
  8 in total
  10 in total

Review 1.  What is known and unknown about chemotherapy-related cognitive impairment in patients with haematological malignancies and areas of needed research.

Authors:  Annalynn M Williams; Clive S Zent; Michelle C Janelsins
Journal:  Br J Haematol       Date:  2016-07-08       Impact factor: 6.998

2.  Promising treatment results with blood brain barrier disruption (BBBD) based immunochemotherapy combined with autologous stem cell transplantation (ASCT) in patients with primary central nervous system lymphoma (PCNSL).

Authors:  Hanne Kuitunen; Susanna Tokola; Topi Siniluoto; Matti Isokangas; Eila Sonkajärvi; Seppo Alahuhta; Taina Turpeenniemi-Hujanen; Esa Jantunen; Tapio Nousiainen; Kaija Vasala; Outi Kuittinen
Journal:  J Neurooncol       Date:  2016-10-17       Impact factor: 4.130

Review 3.  Delivery of chemotherapeutics across the blood-brain barrier: challenges and advances.

Authors:  Nancy D Doolittle; Leslie L Muldoon; Aliana Y Culp; Edward A Neuwelt
Journal:  Adv Pharmacol       Date:  2014-08-22

4.  Blood-brain barrier opening by intracarotid artery hyperosmolar mannitol induces sterile inflammatory and innate immune responses.

Authors:  Scott R Burks; Cymon N Kersch; Jaclyn A Witko; Michael A Pagel; Maggie Sundby; Leslie L Muldoon; Edward A Neuwelt; Joseph A Frank
Journal:  Proc Natl Acad Sci U S A       Date:  2021-05-04       Impact factor: 11.205

5.  Patterns of relapse in primary central nervous system lymphoma: inferences regarding the role of the neuro-vascular unit and monoclonal antibodies in treating occult CNS disease.

Authors:  Prakash Ambady; Rongwei Fu; Joao Prola Netto; Cymon Kersch; Jenny Firkins; Nancy D Doolittle; Edward A Neuwelt
Journal:  Fluids Barriers CNS       Date:  2017-06-02

Review 6.  NIH workshop report on the trans-agency blood-brain interface workshop 2016: exploring key challenges and opportunities associated with the blood, brain and their interface.

Authors:  Margaret J Ochocinska; Berislav V Zlokovic; Peter C Searson; A Tamara Crowder; Richard P Kraig; Julia Y Ljubimova; Todd G Mainprize; William A Banks; Ronald Q Warren; Andrei Kindzelski; William Timmer; Christina H Liu
Journal:  Fluids Barriers CNS       Date:  2017-05-01

Review 7.  Boron delivery agents for neutron capture therapy of cancer.

Authors:  Rolf F Barth; Peng Mi; Weilian Yang
Journal:  Cancer Commun (Lond)       Date:  2018-06-19

8.  Relapsed and refractory primary CNS lymphoma: treatment approaches in routine practice.

Authors:  Prakash Ambady; Nancy D Doolittle; Christopher P Fox
Journal:  Ann Lymphoma       Date:  2021-09

9.  Management of Primary Central Nervous System Lymphoma Using Intra-Arterial Chemotherapy With Osmotic Blood-Brain Barrier Disruption: Retrospective Analysis of the Sherbrooke Cohort.

Authors:  Christian Iorio-Morin; Gérald Gahide; Christophe Morin; Davy Vanderweyen; Marie-André Roy; Isabelle St-Pierre; Karine Massicotte-Tisluck; David Fortin
Journal:  Front Oncol       Date:  2021-01-20       Impact factor: 6.244

10.  Primary central nervous system lymphoma: a narrative review of ongoing clinical trials and goals for future studies.

Authors:  Lauren R Schaff; Prakash Ambady; Nancy D Doolittle; Christian Grommes
Journal:  Ann Lymphoma       Date:  2021-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.